Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03693534
Other study ID # Long-Antagonist-AN005
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 15, 2017
Est. completion date June 30, 2021

Study information

Verified date October 2020
Source Assisting Nature
Contact Evaggelos Papanikolaou, MD,PhD
Phone 00302310424294
Email drvagpapanikolaou@yahoo.gr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A prospective study of the evaluation of the clinical IVF (in vitro fertilization) results after following Long Antagonist protocol for Controlled Ovarian Stimulation (COS) versus following Long Agonist protocol


Description:

A prospective study of the clinical results in women who followed the Long Antagonist protocol for Controlled Ovarian Stimulation (COS) versus women who followed Long Agonist protocol, in an In Vitro Fertilization (IVF) try. In particular, the Clinical Pregnancy Rates (CPR) and Live Birth Rates (LBR) were estimated for the two groups of patients. The number of the formed blastocysts was also measured in each group of patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date June 30, 2021
Est. primary completion date June 30, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 39 Years
Eligibility Inclusion Criteria:

- primary infertility

- age 18-39 years; body mass index (BMI) 18-29kg/m2;

- regular menstrual cycle of 26-35days,

- presumed to be ovulatory;

- early follicular- phase serum concentration of FSH within normal limits (1-12 IU/l).

Exclusion Criteria:

- women with diabetes and other metabolic disease

- women with heart disease, QT prolongation,heart failure

- elevated liver enzymes, liver failure, hepatitis

- women with inflammatory or autoimmune disease

- abnormal karyotype;

- polycystic ovarian syndrome,

- endometriosis stage III/IV;

- history of being a 'poor responder',

- defined as >20 days of gonadotrophin in a previous stimulation cycle, or any previous cancellation of a stimulation cycle due to limited follicular response, or development of less than 4 follicles 15 mm in a previous stimulation cycle; history of recurrent miscarriage; severe OHSS in a previous stimula- tion cycle or any contraindication for the use of gonadotrophins.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Clinical Pregnancy Rate
The Clinical Pregnancy, Live Birth Rate and Blastulation Rate according to the protocol of COS

Locations

Country Name City State
Greece Assisting Nature Thessaloniki

Sponsors (1)

Lead Sponsor Collaborator
Assisting Nature

Country where clinical trial is conducted

Greece, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical Pregnancy Rate according to stimulation protocol Clinical Pregnancy Rate according to stimulation protocol 6 weeks to 42 weeks after embryo transfer
Primary Number of formed blastocysts in each group of patients The number of the formed blastocysts in each group of patients according to the COS protocol 5 days after the OPU day
Secondary Live Birth Rate according to stimulation protocol Live Birth Rate according to stimulation protocol 6 weeks to 42 weeks after embryo transfer
See also
  Status Clinical Trial Phase
Recruiting NCT03463278 - The Number of Blastocysts Formed in the Outcome of Freeze All Strategy: COMFFETI Trial, Cumulative Delivery Rate
Completed NCT02442895 - Biomarkers of Ovarian Reserve and Correlation With IVF Treatments N/A
Completed NCT00773825 - Genomic Imprinting and Assisted Reproductive Technologies N/A
Recruiting NCT03240159 - Long Antagonist Protocol for IVF With Single Luteal Dose of Degarelix Phase 3
Recruiting NCT03684421 - Clinical and Live Birth Rates After Following Long Antagonist Protocol Versus Classical Antagonist Protocol